Seeking Alpha
  • Today - Monday, October 20, 2014

  • 6:35 PM
    • HealthStream (HSTM +0.3%Q3 results: Revenues: $44.5M (+32.0%); Cost of Revenues: $19.1M (+35.5%); Operating Expenses: $39.8M (+33.6%); Net Income: $4.7M (+20.5%); EPS: $0.12 (+50.0%); Quick Assets: $116.4M (+7.6%); CF Ops: $28.7M (+23.7%).
    • Total subscribers implemented: 3.83M, Subscribers contracted: 4.13M. Workforce Development Solutions annualized revenue per implemented subscriber: $35.91 (+16.0%).
    • 2014 guidance: Revenue Growth: 28 - 30% from 26 - 29%, Workforce Development Systems revenue growth: 33 - 35% from 28 - 32%, Research/Patient Experience Solutions revenue growth: 10 - 12% from 15 - 19%; Operating Income: ~$2M (up 5 - 10% yoy) from $2.5M - $3.0M; CAPEX: $9.0M - 10.0M from $9.0M - $12M; tax rate: 37 - 39% from 42 - 44%.
    | Comment!
  • 6:20 PM
    • K2M Group Holdings (KTWO -1.3%) will report Q3 results on October 29 after the close. The conference call will begin at 5:00 pm ET.
    • Consensus view is a loss of ($0.33) per share on revenues of $44M.
    | Comment!
  • 6:14 PM
    • Symmetry Medical (SMA -0.3%) will report Q3 results on October 30 before the open. The conference call will begin at 8:00 am ET.
    • Consensus view is EPS of $0.15 on revenues of $97M.
    | Comment!
  • 5:46 PM
    • Ilumina (ILMN +9.8%Q3 results: Total Revenue: $480.6M (+34.7%), Product Revenue: $416.2M (+30.6%); Cost of Revenue: $146.7M (-0.1%); Operating Expense: $205M (+23.0%); Operating Income: $119.5M (+162.6%); Net Income: $93.5M (+197.8%); EPS: $0.63 (+186.4%); Quick Assets: $1,271.4M (+9.1%); CF Ops: $145.6M (+75.2%).
    • 2014 Guidance: Revenue growth: ~30% from 25-26%; non-GAAP EPS: $2.63 - $2.65 from $2.26-$2.28.
    | Comment!
  • 5:35 PM
    | 1 Comment
  • 5:11 PM
    • Comfortable that the product candidate's development is in good hands, Enanta Pharmaceuticals (ENTA +6.9%) declines to exercise its co-development option with AbbVie (ABBV +1.9%) for ABT-493, Enanta's next-generation protease inhibitor for hepatitis C. It will be eligible for certain regulatory approval milestones as well as royalties on net sales.
    • Enanta reaches agreement with AbbVie on the net sales allocations for royalty calculations for ABT-450-containing regimens as well as those containing ABT-493. For the former, the percentage of annual net sales used to calculate Enanta's royalties is 30% and for the latter it is 45%.
    • Enanta will use its resources to advance its internal HCV candidates, including the NS5A program.
    | Comment!
  • 4:58 PM
    • Exact Sciences (EXAS +0.4%) will report Q3 results on October 27 before the open. The conference call will begin at 9:00 am CT/10:00 am ET.
    • Consensus view is a loss of ($0.32) per share on revenues of $170K.
    | Comment!
  • 4:48 PM
    • TriVascular Technologies (TRIV -1%) will report Q3 results on November 10 after the close. The conference call will begin at 1:30 pm PT/4:30 pm ET.
    • Consensus view is a loss of ($0.63) per share on revenues of $7.9M.
    | Comment!
  • 4:41 PM
    • Foundation Healthcare (FDNH) will report Q3 results on October 29 after the close. The conference call will begin at 3:30 pm CT/4:30 pm ET.
    • Consensus view is EPS of $0.01 on revenues of $24M.
    | Comment!
  • 4:37 PM
    • Janssen Research & Development (JNJ +0.5%) strategic partner Pharmacyclics (PCYC +2.3%) submits an sNDA to the FDA for Imbruvica (ibrutinib) for the treatment of Waldenstrom's macroglobulinemia (WM), a rare type of B-cell lymphoma with no treatment options in the U.S. If approved, it will be the fourth indication for the product.
    • The FDA granted Breakthrough Therapy Designation to Imbruvica for WM in February 2013.
    | Comment!
  • 4:22 PM
    • In data presented at the European Association of Nuclear Medicine Congress in Sweden, Progenics Pharmaceuticals' (PGNX +2.6%) imaging agent candidate, 1404, demonstrated enhanced results in a Phase 2 trial focused on prostate cancer imaging.
    • Imaging with 104 showed 94% sensitivity in detecting and imaging cancer in the prostate gland of high-risk patients prior to prostatectomy. It was more sensitive than MRI in detecting primary prostate cancer (94% vs. 86%) and was a good predictor of lymph node involvement at the time of prostatectomy. SPECT/CT imaging with 1404 identified 14 (19%) more patients with suspicious lymph node sites than MRI.
    • The uptake of 1404 in the lobes of the prostate showed a statistically significant correlation with Gleason score (p<0.0001).
    | Comment!
  • 4:13 PM
    • Illumina (NASDAQ:ILMN): Q3 EPS of $0.77 beats by $0.21.
    • Revenue of $480.63M (+34.7% Y/Y) beats by $29.43M.
    • Shares +7.98%.
    • Press Release
    | Comment!
  • 4:05 PM
    • AstraZeneca (AZN +0.2%) and Bristol-Myers Squibb (BMY +0.3%) win an appeal of an 11-year old whistleblower lawsuit accusing the companies of paying kickbacks to a medical benefits management firm in exchange for purchases and recommendations of drugs they manufacture.
    • The suit was dismissed because the complaint filed by a former employee of the benefits manager did not satisfy the federal False Claims Act's requirement that the whistleblower be the original source of allegations of wrongdoing. The employee, Karl Schumann, sued the companies on behalf of the U.S. and 11 states alleging the firms paid kickbacks to Medco Health Solutions to buy and recommend their brand name drugs. Mr. Schumann sat in meetings at Medco but had no direct independent knowledge of the scheme. His knowledge came from reviewing documents and discussing them with colleagues who were involved.
    • The U.S. declined to participate in the suit after a six-year investigation.
    | Comment!
  • 1:48 PM
    • Santa Barbara, CA-based Sientra (Pending:SIEN) is set for its IPO of 5M shares of common stock at $14 - 16.
    • The medical aesthetics company sells a variety of implants to plastic surgeons, including tissue expanders as well as body contouring and facial implants. Its primary products are silicone breast implants, offered in over 120 variations in size, shape and texture.
    • 2013 Operating Results ($M): Revenues: 35.2 (+238.5%); Gross Profit: 26.6 (+228.4%); Operating Expenses: 44.8 (+42.2%); Operating Loss: (18.2) (+22.2%); Net Loss: (19.1) (+18.4%); Cash Burn Ops: (25.9) (+13.1%).
    • 1H 2014 Operating Results ($M): Revenues: 21.9 (+22.3%); Gross Profit: 16.5 (+21.3%); Operating Expenses: 19.1 (-15.9%); Operating Loss: (2.6) (+71.7%); Net Loss: (1.2) (+87.5%); Quick Assets: 21.6 (pro forma as adjusted: 88.4); CF Ops: 2.2 (+119.0%).
    • S-1
    • ETFs: IBB, BIB, BIS (IPO +0.8%)
    | Comment!
  • 1:15 PM
    • Hanger (NYSE:HGR) will report Q3 results on November 6 after the close. The conference call will begin the next day, November 7, at 9:00 am ET.
    • Consensus view is EPS of $0.45 on revenues of $269M.
    | Comment!
  • 1:03 PM
    • Acadia Healthcare (ACHC +0.2%) will report Q3 results on October 29 after the close. The conference call will begin the next day, October 30, at 9:00 ET.
    • Consensus view is EPS of $0.42 on revenues of $284M.
    | Comment!
  • 12:43 PM
    • The collapse of Abbvie's (ABBV +0.6%) planned takeover of Shire plc (SHPG +2.4%) opens a door for Allergan (AGN +2%) to fend off the hostile bid from Valeant (VRX +2.2%). Institutional shareholder Paulson & Co., which owns stakes in both firms, favors the marriage.
    • Allergan CEO David Pyott received a call from Shire last week. If a deal gets done it will make Allergan too expensive for Valeant to acquire. The chances of a deal appear reasonable. Allergan contacted Shire about a combination some time ago.
    | 3 Comments
  • 12:09 PM
    • Advaxis (ADXS -3%) appoints David J. Mauro, M.D., Ph.D, as EVP, Chief Medical Officer. He will oversee the firm's clinical immuno-oncology programs that utilize Listeria monocytogenes to inhibit tumor growth.
    • Dr. Mauro joins the company from Merck where he was Executive Director, Section Head Oncology Clinical Development.
    | Comment!
  • 12:02 PM
    • Therapix Bio (OTCQB:THXBY) appoints Jan Turek as CEO. He joins the company from the consulting firm TCG LLC where he was a senior strategy and transaction advisor. Previously, he was CEO of Biolex Therapeutics.
    | Comment!
  • 11:55 AM
    • The BOD of Cubist Pharmaceuticals (CBST +1.2%) appoints President and COO Robert J. Perez as Chief Executive replacing the retiring Michael W. Bonney. Mr. Perez was appointed COO in 2007 and President in 2012.
    | Comment!
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector